Navigation Links
ViroPharma Incorporated Reports Third Quarter 2011 Financial Results
Date:10/27/2011

ddress until November 18, 2011.

About ViroPharma Incorporated ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing novel solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options, including C1 esterase inhibitor deficiency, treatment of seizures in children and adolescents, Friedreich's Ataxia (FA), adrenal insufficiency and C. difficile infection (CDI).  Our goal is to provide rewarding careers to employees, to create new standards of care in the way serious diseases are treated, and to build international partnerships with the patients, advocates, and health care professionals we serve.  ViroPharma's commercial products address diseases including hereditary angioedema (HAE) and CDI; for full U.S. prescribing information on our products, please download the package inserts at http://www.viropharma.com/Products.aspx; the prescribing information for other countries can be found at www.viropharma.com

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.

Disclosure Notice Certain statements in this press release contain forward-looking statements that involve a number of risks and uncertainties. Forward-looking statements provide our current expectations or forecasts of future events. Forward looking statements in this press release include our financial guidance for 2011, our ability to successfully commercialize Cinryze and Buccolam in the EU, our ability to complete manufa
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. ViroPharma to Release 2011 Third Quarter Financial Results on October 27, 2011
2. ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreichs Ataxia
3. ViroPharma Announces Additional Securities Repurchase Program
4. ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20)
5. ViroPharmas Buccolam® (Midazolam, Oromucosal Solution) Granted European Marketing Authorization for Treatment of Acute Seizures
6. ViroPharma to Participate in the Stifel Nicolaus 2011 Healthcare Conference
7. ViroPharma Announces Positive CHMP Opinion for Buccolam® (Midazolam, Oromucosal Solution) in the European Union
8. ViroPharmas Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE)
9. ViroPharma to Participate in the Jefferies 2011 Global Healthcare Conference
10. ViroPharma Launches Swell, an Original Documentary Chronicling the Lives of People Living with Hereditary Angioedema
11. ViroPharma Initiates Phase 2 Study of VP 20621 for Prevention of Recurrence of Clostridium difficile Infection (CDI)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... HILL, N.C. , July 31, 2015 /PRNewswire/ ... product success in the biopharmaceutical market. Patients are ... process of selecting and switching therapies. This shift ... is pushing marketers, efforts toward patient-focused marketing. ... patient engagement, marketers have learned it,s important to ...
(Date:7/31/2015)... HILL, N.C. , July 31, 2015  In ... of customers who are increasingly mobile, increasingly connected, and ... a growing variety of customer interaction channels and tools ... technology, including social media. According to ... the over the counter (OTC) segment in a call ...
(Date:7/31/2015)...  Seeger Weiss LLP is reporting that on July 13, ... to C.R. Bard, the manufacturer of Inferior vena cava ... violations the agency found at two of Bard,s facilities. Bard ... cited them during Inspectional Observations that occurred on November 18, ... AZ , location and on October 6, 2014, through ...
Breaking Medicine Technology:Consumers Forcing Pharmaceutical Industry to Shift its Marketing Focus from Products to Patients 2Best Practices in Building World-Class Consumer & Over-the-Counter Call Centers 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 3
... of its Proprietary Technology to Provide Accurate, Fully ... 34th Annual ISCE MeetingSANTA CLARA, Calif., March 31 ... cardiac diagnostic and services company, today announced that ... abstracts and discuss applications for its proprietary technology ...
... published in the Journal of Medicinal Food, ... (1/3 ounce) of "Sun Chlorella A" daily resulted in ... and fasting blood glucose levels.For a 12-week period, 34 ... each morning and evening. Seventeen subjects were healthy; ...
Cached Medicine Technology:NewCardio Leadership to Present Two Abstracts at ISCE Conference 2NewCardio Leadership to Present Two Abstracts at ISCE Conference 3NewCardio Leadership to Present Two Abstracts at ISCE Conference 4First Human Study to Show 'Sun Chlorella A' Supports Heart Health 2
(Date:7/31/2015)... New York (PRWEB) , ... July 31, 2015 , ... ... strut their stuff, Super-Sod debuted their new type of sod called Leisure Time(TM) ... trademark application in process. , To commemorate introduction of this new type of sod, ...
(Date:7/31/2015)... ... July 31, 2015 , ... Precision Aesthetics is New York’s only Thermage skin ... the first provider of Exilis non-surgical fat reduction in New York. Due to ... a large International clientele. Many patients travel to New York to get their ...
(Date:7/31/2015)... ... July 31, 2015 , ... Sculpted Contours Luxury Medical Aesthetics announces the arrival ... Zeltiq Aesthetics released this new applicator in the United States as an upgrade to ... thighs. The original applicator required a 2 hour treatment time. The new ...
(Date:7/31/2015)... Mountain View, CA (PRWEB) , ... July 31, 2015 , ... ... hand for the athletes, judges, media, and VIPs at the 2015 Vans US Open ... best-tasting organic coconut water that can claim “no added sugar” on the market, is ...
(Date:7/31/2015)... CA (PRWEB) , ... July 31, 2015 , ... According ... and cosmetic experts gathered to see if they could reach a consensus on the ... breast augmentation and facelifts. Overall, the group reached 90 percent consensus on a series ...
Breaking Medicine News(10 mins):Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3
... Learn How Their Employee Health Benefit Plans Stack ... owners and human,resource executives grappling with ways to ... effective found out how their plans,compare to others ... Scott Rappoport, a 25-year veteran of the employee ...
... Band Surgery Performed Each Month in UK, ... LONDON, February 1 Today saw the launch of ... and support to people considering obesity surgery. To,coincide with ... survey reveal,widespread confusion over the causes of obesity in ...
... aren,t getting preventive treatments , , THURSDAY, Jan. 31 ... in hospitals worldwide risk developing dangerous blood clots ... treatments that could prevent the condition, a large ... been recognized to be one of the most ...
... Placement of IVIS Systems -, HOPKINTON, Mass., ... CALP ) today announced the shipment of the ... of 2007.,Introduced in 2000, the IVIS molecular imaging ... biological drug,discovery and development research on small living ...
... House Office of Management and Budget evaluates research at ... using the Program Assessment Rating Tool (PART), a set ... their programs, including whether they can measure and demonstrate ... OMB rates research programs as effective, ineffective, or somewhere ...
... Michael J. Fitzpatrick,executive director of the National ... statement:, A media circus and reckless speculation ... Britney Spears and her family. Professional ethics,require that ... treated,individuals not presume to diagnose them. A person,s ...
Cached Medicine News:Health News:Key to Attracting and Retaining Quality Employees: Benefits 2Health News:Key to Attracting and Retaining Quality Employees: Benefits 3Health News:Lose Weight Gain Life: New Website to Help People Seeking Information on Obesity Surgery 2Health News:Lose Weight Gain Life: New Website to Help People Seeking Information on Obesity Surgery 3Health News:Hospital Patients' Blood Clot Risk High 2Health News:Hospital Patients' Blood Clot Risk High 3Health News:Caliper Life Sciences Ships 500th IVIS Imaging System 2Health News:Changes needed in how federal government evaluates efficiency of research at EPA, other agencies 2Health News:Britney Spears: Let's Talk About All of Us 2
... Whether for bypass grafting or creation of ... placed tissue tunnel is of the utmost ... is the answer for those seeking a ... configuration minimizes the risk of twisting or ...
... Cardiovascular Patch utilizes advanced fluoropolymer ... around penetrating suture and decrease ... much as 88 percent. This ... retention, multi-directional strength and low ...
... Vascular Grafts have met the challenges ... Recognized for exceptional performance and quality, ... renowned surgeons worldwide. These grafts require ... spread of infection, and ensure utmost ...
... GORE-TEX Stretch Vascular Grafts have met ... vascular procedures. Recognized for exceptional performance ... endorsement of renowned surgeons worldwide. These ... and the spread of infection, and ...
Medicine Products: